Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1

Next Previous
Search
Trial Profile

A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibalizumab (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Expanded access; Registrational; Therapeutic Use
  • Sponsors TaiMed Biologics

    • Most Recent Events

    • 18 Oct 2022 Results from TMB-301 and TMB-311, characterizing complexity of OBR and assessing its impact on durability of response to IBA, presented in 24th Intl AIDS Conference
    • 21 Jul 2021 Results of subgroup analysis evaluating impact of the post-attachment inhibitor ibalizumab (IBA) on weight as well as potential risk factors in treatment-experienced patients presented at the 11th International AIDS Society Conference on HIV Science
    • 25 Oct 2020 Results presented at the IDWeek 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top